$TSOI: NEWS--NanoStilbene(TM) Nutraceutical Shown

$TSOI: NEWS--NanoStilbene(TM) Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer Recent Data Supports Investigation of Commercially Available Product as an Adjuvant to Chemotherapy for Cancer OCEANSIDE, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- NetworkWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) reported today positive animal data demonstrating synergy at suppressing growth of cancer cells between its commercially available NanoStilbene(TM) nutraceutical product[1] together with cyclophosphamide, a type of chemotherapy. The data indicate that NanoStilbene(TM), a proprietary formulation of pterostilbene [2], may increase the effectiveness of drugs that kill cancer through blocking mechanistic elements of the cell division machinery. "The dogma in oncology has been that chemotherapy efficacy is usually suppressed by agents that act as antioxidants. This is because many types of chemotherapy kill cancer cells by induction of oxidative stress. Interestingly, the recent data suggests a contradictory finding, in that NanoStilbene(TM), which is a proprietary formulation of the antioxidant pterostilbene, actually augments the killing ability of cyclophosphamide, a type of chemotherapy," said Thomas Ichim, Ph.D., Board Member of TSOI and coinventor on the Company's patents. The Company previously reported the results of a clinical trial suggesting the efficacy of NanoStilbene in increased activity of immune system cells termed "Natural Killer" cells, in advanced solid tumor cancer patients, as well as enhancing the production of interferon-gamma, a protein associated with the suppression of cancer growth. The study assessed whether the administration of NanoStilbene was effective at reducing inflammatory markers and augmenting immune function in those 12 advanced cancer patients. Numerous independent laboratories have published in the peer-reviewed literature that pterostilbene decreases the growth of prostate cancer [3], breast cancer [4], glioma [5], liver cancer [6], esophageal cancer [7], and melanoma [8]. The advantage of NanoStilbene(TM) as compared to pterostilbene capsules, which are widely available, is that the proprietary nanoformulation allows substantially higher concentrations of pterostilbene to reach the cancer cells. "Last week we reported data that NanoStilbene(TM) synergizes with immunotherapeutic based drugs. The fact that we are seeing synergy with drugs that kill cancer through completely different mechanisms suggests that our approach is targeting multiple pathways in cancer and that at least conceptually, tumor resistance to pterostilbene based products should be rarer than for other drugs," said Timothy Dixon, President, and CEO of the Company. "We plan to expand these studies to see whether NanoStilbene(TM) synergizes with other types of chemotherapies."

Sojourner here following God, obeying God, and cleaving to Him. The journey is onward.